CS
GH icon

Candriam SCA’s Guardant Health GH Stock Holding History

Candriam SCA’s Portfolio GH Stock Details GH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.5M Buy
90,197
+981
+1% +$107K 0.06% 250
2026
Q1 		$8.24M Sell
89,216
-59,190
-40% -$5.94M 0.04% 310
2025
Q4 		$15.2M Sell
148,406
-23,347
-14% -$2.09M 0.08% 219
2025
Q3 		$10.7M Buy
171,753
+1,231
+0.7% +$67K 0.06% 263
2025
Q2 		$8.87M Sell
170,522
-2,352
-1% -$105K 0.05% 266
2025
Q1 		$7.36M Sell
172,874
-179,618
-51% -$7.75M 0.05% 272
2024
Q4 		$10.8M Sell
352,492
-13,653
-4% -$384K 0.06% 251
2024
Q3 		$8.4M Hold
366,145
– – 0.05% 290
2024
Q2 		$10.6M Sell
366,145
-99,992
-21% -$2.33M 0.06% 249
2024
Q1 		$9.62M Hold
466,137
– – 0.06% 260
2023
Q4 		$12.6M Sell
466,137
-25,000
-5% -$656K 0.09% 223
2023
Q3 		$14.6M Sell
491,137
-68,225
-12% -$2.4M 0.1% 185
2023
Q2 		$20M Buy
559,362
+38,180
+7% +$1.1M 0.14% 156
2023
Q1 		$11.2M Buy
521,182
+61,538
+13% +$1.76M 0.08% 241
2022
Q4 		$12.5M Buy
459,644
+270,594
+143% +$12.4M 0.08% 228
2022
Q3 		$10.2M Buy
189,050
+39,469
+26% +$2.03M 0.07% 266
2022
Q2 		$6.03M Buy
149,581
+10,000
+7% +$495K 0.05% 300
2022
Q1 		$9.25M Sell
139,581
-7,708
-5% -$527K 0.06% 269
2021
Q4 		$14.7M Buy
147,289
+22,917
+18% +$2.37M 0.09% 210
2021
Q3 		$15.5M Buy
124,372
+26,676
+27% +$3.17M 0.11% 208
2021
Q2 		$12.1M Buy
97,696
+9,344
+11% +$1.26M 0.08% 261
2021
Q1 		$10.9M Hold
88,352
– – 0.09% 238
2020
Q4 		$11.4M Sell
88,352
-3,986
-4% -$459K 0.09% 242
2020
Q3 		$10.3M Buy
92,338
+13,751
+17% +$1.26M 0.1% 224
2020
Q2 		$6.38M Buy
78,587
+20,829
+36% +$1.68M 0.07% 291
2020
Q1 		$4.41M Buy
57,758
+6
+0% +$460 0.05% 383
2019
Q4 		$4.51M Buy
57,752
+47,552
+466% +$3.43M 0.05% 392
2019
Q3 		$651K Sell
10,200
-4,590
-31% -$404K 0.01% 660
2019
Q2 		$5.49M Buy
14,790
+8,590
+139% +$656K 0.07% 310
2019
Q1 		$476K Buy
+6,200
New +$344K 0.01% 717

Other funds holding GH

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Candriam SCA's GH Position: Q2 2026 in Review

Candriam SCA increased its Guardant Health (GH) stake by 1.1% in Q2 2026, buying an estimated $107K and bringing the position to 90,197 shares worth $13.5M. The position accounts for 0.06% of the portfolio, ranked #250.

Candriam SCA first reported a position in GH in Q1 2019 and has held it in 30 quarters since. The position peaked at $20M in Q2 2023. 597 funds tracked by Wall St. Rank hold GH as of Q2 2026.

  • Candriam SCA held 90,197 shares of Guardant Health worth $13.5M as of Q2 2026.
  • Candriam SCA bought 981 Guardant Health shares in Q2 2026, an estimated $107K.
  • Guardant Health made up 0.06% of Candriam SCA's portfolio in Q2 2026, its #250 holding.
  • Candriam SCA first reported a position in Guardant Health in Q1 2019 and has held it in 30 quarters since.
  • Candriam SCA's Guardant Health position peaked at $20M in Q2 2023.
  • 597 funds tracked by Wall St. Rank held Guardant Health as of Q2 2026.

Based on Candriam SCA's 13F filing for Q2 2026, filed 13 Aug 2026.